Form 4: Tandem Diabetes Care: Officer Reports Acquisition of Restricted and Performance Stock Units

Shannon Marie Hansen, Chief Legal Officer of Tandem Diabetes Care, reports the acquisition of restricted stock units and performance stock units.

Summary

• Shannon Marie Hansen, Chief Legal Officer of Tandem Diabetes Care Inc., filed a Form 4 on May 28, 2024, reporting transactions related to the company's stock.
• The report details the acquisition of 13,161 restricted stock units (RSUs) and 13,160 performance stock units (PSUs) on May 23, 2024.
• Hansen directly owns 8,413 shares of common stock and indirectly owns 1,935 shares through the Shannon M. Hansen Trust.
• The RSUs vest over time, starting with 33% on May 15, 2025, and the remainder in equal quarterly installments.
• The PSUs vest based on the achievement of predefined performance metrics as of December 31, 2026, with the number of shares issued ranging from 0% to 200% of the specified amount.

Sentiment

Score: 6

Explanation: The document is a standard regulatory filing detailing stock-based compensation. It's neutral in tone and doesn't indicate any significant positive or negative developments for the company.

Positives

• The acquisition of RSUs and PSUs aligns the officer's interests with the company's performance and long-term success.
• The vesting schedules for RSUs and PSUs encourage continued service and achievement of performance goals.

Risks

• The value of the RSUs and PSUs is contingent on the company's stock price and performance, which are subject to market risks.
• If minimum performance metrics are not met, no PSUs will vest, potentially impacting the officer's compensation.

Future Outlook

The vesting of RSUs and PSUs is dependent on continued service and, in the case of PSUs, the achievement of predefined performance metrics by December 31, 2026.

Industry Context

This filing is a routine disclosure related to executive compensation and is common in publicly traded companies. It reflects the company's compensation strategy to align executive interests with shareholder value.

Comparison to Industry Standards

• Granting restricted stock units and performance stock units is a common practice among publicly traded companies, including those in the medical device industry, such as Insulet (PODD) and Dexcom (DXCM).
• Vesting schedules and performance metrics vary, but the general structure of these awards is consistent with industry norms for incentivizing and retaining key executives.
• The specific performance metrics for the PSUs are not disclosed, but they likely relate to financial performance, strategic goals, or other key performance indicators relevant to Tandem Diabetes Care's business.

Stakeholder Impact

• The granting of RSUs and PSUs can positively impact shareholders by aligning management's interests with the company's long-term performance.
• Employees may be motivated by the potential for stock-based compensation, contributing to employee retention and productivity.

Key Dates